Zymogenetics, Inc.is focused on the discovery, development, manufacture and commercialization of therapeutic proteins for the treatment of human diseases. The Company's therapeutic focus is in the areas of hemostasis, inflammatory and autoimmune diseases, cancer and viral infections. Its first internally developed product candidate, RECOTHROM Thrombin ((also referred to as rThrombin), topical (Recombinant), was approved by the United States Food and Drug Administration (FDA) on January 17, 2008, for use as a topical hemostat to control moderate bleeding during surgical procedures and is being marketed in the United States.